Femarelle launches new women’s supplement line in US
Targeted formulas support symptoms before, during and after menopause.
Israel-based Se-cure Pharmaceuticals has announced its US launch of Femarelle, a premium supplement line for women over 40. The Femarelle line includes three products, each one formulated for a different stage of estrogen decline, before, during and after menopause.
Femarelle is developed from a proprietary extract, DT56a, which has been shown in clinical studies to support healthy management of menopause symptoms. Because the symptoms of estrogen decline vary from ages 40-70+, each product provides a targeted solution with additional ingredients to address the needs of the individual.
“Femarelle is a natural option to relieve the symptoms of menopause,” said Dr Margaret Nachtigall, a founding member of the North American Menopause Society and a noted reproductive endocrinologist. “The inevitable decline in estrogen levels is experienced differently by women at different stages of life, so having three unique products ensures specific symptoms get targeted attention at the right time.”
Backed by 19 published studies in the most prestigious scientific journals, Femarelle® offers compelling, consistent and validated results for women 40 and beyond. Femarelle contains no soy isoflavones, plus each formula is tissue-specific in its mode of action for maximum focused effort and results.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.